USA: +1 347 690-0211 | UK: +44 2032 894158 | Translate :
[225+ Pages Report] The recent research report issued by Facts and Factors states that the global breast cancer treatment market was registered at about USD 19.24 Billion in 2019, and is expected to generate revenues worth around USD 34.06 Billion by end of 2026, effectively growing at a CAGR of around 8.5% between 2020 and 2026.
Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the breast and red patches on the skin. Obesity, lack of physical activity, excessive radiation exposure, and alcohol use are all risk factors for breast cancer. Breast cancer is more prevalent in developed countries than it is in developing countries.
The rising number of females diagnosed with breast cancer is a major driver of market development. Aside from this, the demand has grown due to the acceptance of unhealthy lifestyles, an increase in the women geriatric population, exposure to toxic radiation, and increased government initiatives. Since no absolute cure exists, there is room for the industry to develop globally. On the other hand, the market's growth is being stifled by the high cost of medication, side effects associated with therapy, and the long time it takes for medications to be approved.
Invasive lobular carcinoma, invasive ductal carcinoma, and others are the three types of breast cancer that make up the global market. Surgery & radiation therapy, targeted therapy, chemotherapy, hormone therapy, biologic therapy, and others are the medication categories. Alkylating agents, antimetabolites, taxanes, and anthracyclines, are the different types of chemotherapy. Tyrosine kinase inhibitors and monoclonal antibodies are two types of target therapy, aromatase inhibitors, selective estrogen-receptor modulators and other types of hormone therapy are available. The industry is divided into three categories based on end-users: hospital pharmacies, private pharmacies, and others.
The global breast cancer treatment market is driven by America on a regional basis. The demand has grown as a result of changing lifestyles and the increased incidence of breast cancer in the United States. Europe is the market leader in breast cancer. The development of this market in America and Europe is due to technological advancements, increased life expectancy, and increased healthcare spending by people. The market is expected to expand at the fastest rate in the Asia Pacific. Various organizations' efforts to raise awareness, educate the masses, and raise the funds for the disease are expected to propel regional development.
Key participants in breast cancer treatment market Pfizer, AstraZeneca, BioNumerik Pharmaceuticals, Eli Lilly and Company, Novartis AG, Apthera Inc., Puma Biotechnology, Gilead Sciences, Inc., Bipar Sciences, Oncogenex, Astellas, Teva Pharmaceutical Industries, Sanofi S.A., Genentech, and others.
Copyright © 2022 - 2023, All Rights Reserved, Facts and Factors